Literature DB >> 21752954

Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation.

David Hallengärd1, B Kristian Haller, Anna-Karin Maltais, Eva Gelius, Kopek Nihlmark, Britta Wahren, Andreas Bråve.   

Abstract

In vivo electroporation (EP) has proven to significantly increase plasmid transfection efficiency and to augment immune responses after immunization with plasmids. In this study, we attempted to establish an immunization protocol using intradermal (i.d.) EP. BALB/c mice were immunized with a plasmid encoding HIV-1 p37Gag, either i.d. with the Derma Vax EP device, intramuscularly (i.m.) without EP, or with combinations of both. A novel FluoroSpot assay was used to evaluate the vaccine-specific cellular immune responses. The study showed that i.d. EP immunizations induced stronger immune responses than i.m. immunizations using a larger amount of DNA and that repeated i.d. EP immunizations induced stronger immune responses than i.m. priming followed by i.d. EP boosting. Two and three i.d. EP immunizations induced immune responses of similar magnitude, and a short interval between immunizations was superior to a longer interval in terms of the magnitude of cellular immune responses. The FluoroSpot assay allowed for the quantification of vaccine-specific cells secreting either gamma interferon (IFN-γ), interleukin-2 (IL-2), or both, and the sensitivity of the assay was confirmed with IFN-γ and IL-2 enzyme-linked immunosorbent spot (ELISpot) assays. The data obtained in this study can aid in the design of vaccine protocols using i.d. EP, and the results emphasize the advantages of the FluoroSpot assay over traditional ELISpot assay and intracellular staining for the detection and quantification of bifunctional vaccine-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752954      PMCID: PMC3165233          DOI: 10.1128/CVI.05045-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

1.  Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery.

Authors:  Andreas Bråve; Karl Ljungberg; Andreas Boberg; Erik Rollman; Maria Isaguliants; Björn Lundgren; Pontus Blomberg; Jorma Hinkula; Britta Wahren
Journal:  Mol Ther       Date:  2005-08-22       Impact factor: 11.454

Review 2.  DNA vaccines for aquacultured fish.

Authors:  N Lorenzen; S E LaPatra
Journal:  Rev Sci Tech       Date:  2005-04       Impact factor: 1.181

3.  IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays.

Authors:  Stefan Quast; Wenji Zhang; Carey Shive; Damian Kovalovski; Patrick A Ott; Bernhard A Herzog; Bernhard O Boehm; Magdalena Tary-Lehmann; Alexey Y Karulin; Paul V Lehmann
Journal:  Cell Immunol       Date:  2005-10-27       Impact factor: 4.868

4.  Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein.

Authors:  S Schwartz; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Authors:  Zhi-yong Yang; Linda S Wyatt; Wing-Pui Kong; Zoe Moodie; Bernard Moss; Gary J Nabel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 6.  Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery.

Authors:  S Babiuk; M Baca-Estrada; L A Babiuk; C Ewen; M Foldvari
Journal:  J Control Release       Date:  2000-05-15       Impact factor: 9.776

7.  Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.

Authors:  M J McCluskie; C L Brazolot Millan; R A Gramzinski; H L Robinson; J C Santoro; J T Fuller; G Widera; J R Haynes; R H Purcell; H L Davis
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

8.  Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Authors:  Sarah Buchan; Eirik Grønevik; Iacob Mathiesen; Catherine A King; Freda K Stevenson; Jason Rice
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

Review 9.  Anatomy, histology and immunohistochemistry of normal human skin.

Authors:  Jean Kanitakis
Journal:  Eur J Dermatol       Date:  2002 Jul-Aug       Impact factor: 3.328

10.  In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.

Authors:  Sandhya Vasan; Arlene Hurley; Sarah J Schlesinger; Drew Hannaman; David F Gardiner; Daniel P Dugin; Mar Boente-Carrera; Roselle Vittorino; Marina Caskey; Johanne Andersen; Yaoxing Huang; Josephine H Cox; Tony Tarragona-Fiol; Dilbinder K Gill; Hannah Cheeseman; Lorna Clark; Len Dally; Carol Smith; Claudia Schmidt; Harriet H Park; Jakub T Kopycinski; Jill Gilmour; Patricia Fast; Robert Bernard; David D Ho
Journal:  PLoS One       Date:  2011-05-16       Impact factor: 3.240

View more
  17 in total

1.  Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Authors:  Jamie F S Mann; Paul F McKay; Anezka Fiserova; Katja Klein; Alethea Cope; Paul Rogers; Julie Swales; Michael S Seaman; Behazine Combadiere; Robin J Shattock
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

2.  A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines.

Authors:  Silvia Massa; Francesca Paolini; Gianfranca Curzio; Marcelo Nazario Cordeiro; Elena Illiano; Olivia Costantina Demurtas; Rosella Franconi; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2017-01-24       Impact factor: 3.452

3.  Evaluation of immunogen delivery by DNA immunization using non-invasive bioluminescence imaging.

Authors:  Stefan P Petkov; Frank Heuts; Olga A Krotova; Athina Kilpelainen; Gunnel Engström; Elizaveta S Starodubova; Maria G Isaguliants
Journal:  Hum Vaccin Immunother       Date:  2013-07-03       Impact factor: 3.452

4.  Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.

Authors:  Anne Chauvat; Nadine Benhamouda; Alain Gey; Francois M Lemoine; Staffan Paulie; Fabrice Carrat; Marie-Lise Gougeon; Flore Rozenberg; Anne Krivine; Mustapha Cherai; Paul Lehmann; Françoise Quintin-Colonna; Odile Launay; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2013-10-01       Impact factor: 3.452

5.  Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.

Authors:  David Hallengärd; Maria Kakoulidou; Aleksei Lulla; Beate M Kümmerer; Daniel X Johansson; Margit Mutso; Valeria Lulla; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Peter Liljeström
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

Review 6.  Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?

Authors:  Guido Vanham; Ellen Van Gulck
Journal:  Retrovirology       Date:  2012-09-07       Impact factor: 4.602

7.  Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.

Authors:  Nicolas Ruffin; Marie Borggren; Zelda Euler; Fabio Fiorino; Katrijn Grupping; David Hallengärd; Aneele Javed; Kevin Mendonca; Charlotte Pollard; David Reinhart; Elisa Saba; Enas Sheik-Khalil; Annette Sköld; Serena Ziglio; Gabriella Scarlatti; Frances Gotch; Britta Wahren; Robin J Shattock
Journal:  J Transl Med       Date:  2012-07-11       Impact factor: 5.531

8.  A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.

Authors:  David Hallengärd; Andreas Bråve; Maria Isaguliants; Pontus Blomberg; Jenny Enger; Richard Stout; Alan King; Britta Wahren
Journal:  Genet Vaccines Ther       Date:  2012-08-08

9.  FluoroSpot Analysis of TLR-Activated Monocytes Reveals Several Distinct Cytokine-Secreting Subpopulations.

Authors:  C Smedman; T Ernemar; L Gudmundsdotter; P Gille-Johnson; A Somell; K Nihlmark; B Gårdlund; J Andersson; S Paulie
Journal:  Scand J Immunol       Date:  2012-02       Impact factor: 3.487

10.  Multifarious immunotherapeutic approaches to cure HIV-1 infection.

Authors:  Nesrina Imami; Anna A Herasimtschuk
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.